Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Louisa Bolm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1612-1857; OpenAlex author ID A5080802199. Sources: OpenAlex.

Their work

Papers
34 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 6 papers · 2021: 4 papers · 2022: 3 papers · 2023: 5 papers · 2024: 3 papers · 2025: 5 papers · 2026: 3 papers

Papers 34

  1. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
  2. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… Co-author DOI 10.1097/sla.0000000000006432↗
  3. Octogenarians and Pancreatic Cancer: Is Surgery Always the Right Choice? Co-author DOI 10.3390/cancers18152423↗
  4. An R0 resection margin does improve overall survival after PDAC resection- real-world evidence from 6.000 cases from the German Cancer Registry Group. Co-author DOI 10.1016/j.ejso.2025.109693↗
  5. Preoperative Biopsy Is Not Associated With Adverse Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Upfront Resection. First author DOI 10.1016/j.jss.2025.01.007↗
  6. The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyaf083↗
  7. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… Co-author DOI 10.1097/sla.0000000000006719↗
  8. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  9. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Last author DOI 10.1016/j.surg.2023.11.004↗
  10. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  11. Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic D… Co-author DOI 10.3390/cancers16112016↗
  12. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  13. Recent onset diabetes is associated with better survival in pancreatic ductal adenocarcinoma-An analysis of preoperative symptoms within the DGAV StuDoQ|Pancre… Co-author DOI 10.1016/j.surg.2023.04.042↗
  14. Overexpression of integrin alpha 2 (ITGA2) correlates with poor survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2022-208176↗
  15. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Co-author DOI 10.3389/fonc.2023.1230382↗
  16. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. Co-author DOI 10.3390/cells12040587↗
  17. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. Co-author DOI 10.1055/a-1768-1012↗
  18. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  19. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Co-author DOI 10.3390/cancers14040868↗
  20. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Co-author DOI 10.1007/s00423-021-02138-4↗
  21. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.11.015↗
  22. Postoperative Outcomes of Tangential versus Segmental Resection and End-to-end Reconstruction of the Superior Mesenterico-Portal Vein During Pancreatoduodenect… Last author DOI 10.21873/anticanres.15329↗
  23. Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis. Co-author DOI 10.3791/62541↗
  24. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-019-02719-1↗
  25. Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. Co-author DOI 10.1007/s10456-020-09725-x↗
  26. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  27. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  28. Alignment of stroma fibers, microvessel density and immune cell populations determine overall survival in pancreatic cancer-An analysis of stromal morphology. Co-author DOI 10.1371/journal.pone.0234568↗
  29. Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients-Proposal of a New Simplified Borderline Resectabilit… Co-author DOI 10.3390/cancers12040882↗
  30. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  31. Kidney Transplantation after Extended Multivisceral Resection for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1155/2018/3757382↗
  32. The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors. Co-author DOI 10.1016/j.tranon.2017.04.009↗
  33. Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1363-2↗
  34. Predicting Survival After Irradiation of Metastases from Pancreatic Cancer. Co-author PMID 26124362↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ulrich Friedrich Wellner · 26 shared papers, 2015–2026 · strength 3.33
  2. Tobias Keck · 25 shared papers, 2016–2026 · strength 3.23
  3. Kim C. Honselmann · 19 shared papers, 2020–2026 · strength 2.84
  4. Rüdiger Braun · 14 shared papers, 2021–2026 · strength 2.21
  5. Steffen Deichmann · 12 shared papers, 2020–2026 · strength 1.89
  6. Hryhoriy V. Lapshyn · 14 shared papers, 2016–2026 · strength 1.84
  7. Keith D. Lillemoe · 8 shared papers, 2020–2026 · strength 1.56
  8. Motaz Qadan · 7 shared papers, 2020–2026 · strength 1.35
  9. Natalie Petruch · 6 shared papers, 2021–2025 · strength 1.01
  10. Maximiliano Servín-Rojas · 4 shared papers, 2024–2026 · strength 0.91
  11. Dirk Bausch · 8 shared papers, 2016–2021 · strength 0.78
  12. Thaer S. A. Abdalla · 4 shared papers, 2024–2026 · strength 0.75
  13. Cristina Rosa Ferrone · 4 shared papers, 2022–2026 · strength 0.74
  14. Zhi Ven Fong · 3 shared papers, 2024–2026 · strength 0.74
  15. Ekaterina Petrova · 7 shared papers, 2019–2022 · strength 0.73
  16. Carlos Fernández-del Castillo · 3 shared papers, 2022–2026 · strength 0.69
  17. Carlos F. Fernandez-del Castillo · 4 shared papers, 2020–2025 · strength 0.59
  18. Lennart von Fritsch · 3 shared papers, 2024–2026 · strength 0.58
  19. Benedikt Färber · 3 shared papers, 2023–2026 · strength 0.52
  20. Taisuke Baba · 3 shared papers, 2022–2025 · strength 0.44
  21. Jon Michael Harrison · 3 shared papers, 2022–2025 · strength 0.44
  22. Andrew Louis Warshaw · 3 shared papers, 2020–2025 · strength 0.42
  23. Guoliang Qiao · 2 shared papers, 2024–2025 · strength 0.39
  24. Benjamin Heckelmann · 2 shared papers, 2023–2026 · strength 0.37
  25. Jens Uwe Marquardt · 2 shared papers, 2023–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.